BRIEF published on 09/18/2024 at 07:05, 2 years ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 2 years ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 2 years 1 month ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 2 years 1 month ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 2 years 1 month ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 2 years 1 month ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 2 years 2 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 2 years 2 months ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 2 years 3 months ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 2 years 3 months ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 10/06/2026 at 16:45, 1 hour 6 minutes ago Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 10/06/2026 at 16:30, 1 hour 21 minutes ago Snipp Survey Finds AI is Reshaping the Shopper Journey, with 61.8% of AI Users Having Purchased After an AI Recommendation
Published on 10/06/2026 at 15:45, 2 hours 6 minutes ago Stagwell Launches New Global Media Agency, Stagwell Media
Published on 10/06/2026 at 15:00, 2 hours 51 minutes ago Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Published on 10/06/2026 at 14:31, 3 hours 20 minutes ago Worksport (Nasdaq: WKSP) Books $2.92M August Orders; Annualized Order Run Rate Reaches $35M
Published on 10/06/2026 at 17:45, 6 minutes ago EQS-Adhoc: Airbus SE: Airbus reports share buyback transactions 28 Sept. to 02 Oct. 2026
Published on 10/06/2026 at 17:08, 42 minutes ago EQS-Adhoc: Bio-Gate AG: Revises Revenue and Earnings Forecast for Fiscal Year 2026
Published on 10/06/2026 at 17:06, 45 minutes ago Bitcoin Group SE: futurum bank AG prepares alternative operating model for Bitcoin.de
Published on 10/06/2026 at 17:05, 46 minutes ago EQS-Adhoc: Bitcoin Group SE: Bafin refuses MiCAR authorisation applied for by futurum bank AG
Published on 10/06/2026 at 17:45, 6 minutes ago Aéroports de Paris SA - Shares and voting rights as of 30 Septembre 2026
Published on 10/06/2026 at 17:45, 6 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 10/06/2026 at 17:35, 16 minutes ago Disclosure of the number of shares and the total number of voting rights as of September 30, 2026
Published on 10/05/2026 at 22:12, 19 hours 39 minutes ago AXA - Elimination of the dilutive impact of Shareplan 2026
